CE-245677 mesylate

[1]. Bagal SK, et al. Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain. Journal of medicinal chemistry. 2018 Aug 09;61(15):6779-6800. [Content Brief]

[2]. Yamada T, et al. Discovery and hit to lead optimization of macrocyclic peptides as novel tropomyosin receptor kinase A antagonists. Journal of Medicinal Chemistry. 2024 Jul 1;67(13):11197-208. [Content Brief]

[3]. Bagal SK, et al. Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. Journal of medicinal chemistry. 2019 Jan 10;62(1):247-265.

[4]. Wang T, et al. Trk kinase inhibitors as new treatments for cancer and pain. Expert opinion on therapeutic patents. 2009 Mar 1;19(3):305-19.

[5]. LaGreca S, et al. Identification of selective, orally active Tie2 kinase inhibitors and discovery of CE-245,677 and PF-371,989. Cancer Research. 2007 May 1;67(9_Supplement):3259-.

[6]. Lotharius J, et al. Repositioning: the fast track to new anti-malarial medicines?. Malaria journal. 2014 Apr 14;13:143.

[7]. Skerratt SE, et al. The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Journal of medicinal chemistry. 2016 Nov 23;59(22):10084-10099. [Content Brief]